摘要
非小细胞肺癌患者间变性淋巴瘤激酶(ALK)突变率为3%~7%。与表皮生长因子受体阳性非小细胞肺癌患者比较, ALK突变非小细胞肺癌患者更易获得长期生存, 因此, ALK突变被称为钻石突变。目前, 在全球范围内, ALK-酪氨酸激酶抑制剂(TKI)药物已经有三代药物。中国已获批的ALK-TKI第一代药物为克唑替尼, 第二代药物为阿来替尼、塞瑞替尼和恩沙替尼。恩沙替尼为中国自主原研的ALK-TKI, 其疗效与阿来替尼相似, 耐受性表现为一过性皮疹, 从患者长期生存的角度而言, 顺应性更好。恩沙替尼引起的皮疹表现与其他ALK-TKI药物不同, 为了便于临床应用和为患者提供更多的治疗选择, 在中国抗癌协会肿瘤康复与姑息治疗专业委员会的指导下, 专家收集汇总了恩沙替尼常见的不良反应, 并结合临床实践制定了明确的不良分级及具体处理方案, 以期为临床医师提供相应的参考依据。
The mutation rate of anaplastic lymphoma kinase(ALK)in patients with non-small cell lung cancer is 3%to 7%.Due to its low mutation rate and better long-term survival compared with epidermal growth factor receptor-positive non-small cell lung cancer patients,therefore,it′s called"diamond mutation".At present,there are three generations of ALK tyrosine kinase inhibitor(TKI)drugs in the world.The first-generation ALK-TKI drug approved in China is crizotinib,and the second-generation drugs are alectinib,ceritinib and ensartinib.Among them,ensartinib is an ALK-TKI domestically developed,and its efficacy is similar to that of alectinib.The main adverse event is transient rash,and compliance to ensartinib is better from the perspective of long-term survival of patients.The manifestation of rash caused by ensartinib is different from that of other ALK-TKI drugs.In order to facilitate clinical application and provide patients with more treatment options,under the guidance of the Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association,this article collects and summarizes the common adverse reactions of ensartinib.Based on the clinical practice,a clear adverse classification and specific treatment plan are formulated,in order to provide a corresponding reference for clinicians to make more comprehensive clinical decisions.
作者
张力
杨云鹏
中国抗癌协会肿瘤康复与姑息治疗专业委员会
恩沙替尼治疗间变性淋巴瘤激酶阳性非小细胞肺癌专家共识制定顾问专家组
Zhang Li;Yang Yunpeng;Committee of Cancer Rehabilitation and Palliative Care of China Anti-Cancer Association;Expert Panel for Expert Consensus Development of Ensartinib in the Treatment of Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer(Department of Medical Oncology,Sun Yat-Sen University Cancer Center,Guangzhou 510060;不详)
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2022年第4期297-306,共10页
Chinese Journal of Oncology
作者简介
通信作者:张力,中山大学肿瘤防治中心肿瘤内科,广州510060,Email:zhangli@sysucc.org.cn。
